Metastatic Melanoma Therapeutics Market Report 2025

The metastatic melanoma therapeutics market size has grown rapidly in recent years. It will grow from $8.28 billion in 2024 to $9.31 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to pioneering immunotherapy approval, targeted therapy innovations, clinical trial successes, introduction of combination therapies, advancements in diagnostic technologies.

The metastatic melanoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $14.71 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to expanding patient pool, research and development initiatives, biomarker identification, accelerated regulatory approvals, market expansion into emerging economies. Major trends in the forecast period include immunotherapy combinations, precision medicine advances, emerging targeted therapies, adjuvant therapies after surgery, development of bi-specific antibodies.

The anticipated growth in the metastatic melanoma therapeutics market is expected to be propelled by two significant factors. Firstly, the rising incidence of melanoma cases is poised to contribute to market expansion. Melanoma, a form of skin cancer originating in melanocytes, the pigment-regulating cells in the skin, can occur anywhere on the skin. Metastatic melanoma therapeutics encompass various treatments designed to block mutant chemicals and impede the growth of melanoma cells while minimizing harm to healthy tissue. According to the American Cancer Society, it is estimated that there will be 58,120 new cases of melanomas diagnosed in males and 39,490 in females in the US in 2023, totaling around 97,610 cases, with approximately 7,990 predicted deaths. The rising incidence of melanoma is a key driver for the growth of the metastatic melanoma therapeutics market.

The growing demand for biologics is expected to further propel market growth. Biologics, therapeutic products derived from living organisms or containing components of living organisms, have transformed the treatment landscape for metastatic melanoma. They offer targeted and immunotherapy-based approaches that have significantly improved patient outcomes with minimal side effects compared to traditional chemotherapy. For instance, according to the US Food and Drug Administration reported that by the end of 2022, 40 biosimilars had received approval, with 27 of them available in the United States, providing alternatives to 10 brand-name biologics. The growing demand for biologics, with their targeted and immunotherapy benefits, is a significant driver for the metastatic melanoma therapeutics market.

The metastatic melanoma therapeutics market is currently witnessing a significant trend towards product innovations, with companies strategically leveraging recent technologies to enhance their market standing. Notably, in January 2022, UK-based biotechnology firm Immunocore obtained FDA approval for KIMMTRAK, the first-ever FDA-approved T cell receptor (TCR) therapy designed for treating unresectable or metastatic uveal melanoma. Developed using Immunocore's ImmTAC technology platform, KIMMTRAK demonstrated a noteworthy overall survival (OS) advantage, boasting a hazard ratio of 0.51 and a median OS of nearly 22 months.

Leading companies in the metastatic melanoma therapeutics sector are actively engaging in strategic collaborations to assess treatments for metastatic cutaneous melanoma. An example of this is the collaboration between Immunocore and Sanofi, announced in June 2022. The partnership involves a clinical trial collaboration and supply agreement, wherein Sanofi will evaluate its engineered IL-2, SAR444245, in combination with Immunocore's KIMMTRAK in patients with advanced unresectable or metastatic skin cancers.

In April 2022, Germany-based investment firm EMZ Partners acquired a majority stake in FotoFinder Systems GmbH, a move undisclosed in terms of financial details. This strategic partnership aims to facilitate FotoFinder Systems GmbH's expansion of its product portfolio and market reach. FotoFinder Systems GmbH specializes in providing skin visualization equipment utilized in melanoma therapeutics.

Major companies operating in the metastatic melanoma therapeutics market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Ltd., Eisai Co. Ltd., Incyte Corporation, Exelixis Inc., BeiGene Ltd, Immunocore Holdings plc, Genentech Inc., Iovance Biotherapeutics Inc., Nektar Therapeutics, Adaptimmune Therapeutics plc, AIVITA Biomedical Inc., Idera Pharmaceuticals Inc., Evaxion Biotech A/S, AB Science, AgonOX Inc., InxMed Co. Ltd., NewLink Genetics Corporation, Vical Inc.

North America was the largest region in the metastatic melanoma therapeutics market in 2024. The regions covered in the metastatic melanoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metastatic melanoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Metastatic melanoma therapeutics encompass a range of treatment options available for individuals diagnosed with metastatic melanoma, a type of skin cancer that has spread to other parts of the body. Melanoma arises from the transformation of pigmented cells called melanocytes, leading to the formation of tumors.

The primary types of metastatic melanoma therapeutics include chemotherapy, immunotherapy, targeted therapy, radiation therapy, and surgery. Chemotherapy involves the use of potent chemicals to eliminate rapidly proliferating cells in the body. The treatment may be administered at various stages, including stage 0, stage I, stage II, stage III, and stage IV, depending on the extent of the cancer. These therapeutic options are utilized by various healthcare providers, including hospitals, specialty clinics, home healthcare, and other medical facilities.

The metastatic melanoma therapeutics market research report is one of a series of new reports that provides metastatic melanoma therapeutics market statistics, including metastatic melanoma therapeutics industry global market size, regional shares, competitors with a metastatic melanoma therapeutics market share, detailed metastatic melanoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic melanoma therapeutics industry. This metastatic melanoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metastatic melanoma therapeutics market consists of sales of surgical resection, lymph node dissection, and lymphatic mapping and sentinel lymph node biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic melanoma therapeutics market also includes sales of trametinib (Mekinist), cobimetinib (Cotellic), and binimetinib (Mektovi). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.